The Untapped Potential of Office-Based Buprenorphine Treatment

February 14, 2015

Opioid abuse and dependence are reaching epidemic proportions in the United States, resulting in a staggering number of overdose deaths and economic costs that exceed $56 billion annually. Medication-assisted therapies, such as buprenorphine (Suboxone) and methadone, represent the most efficacious treatments for opioid dependence. Office-based buprenorphine treatment is especially well positioned to provide a rapid […]

Read the full article →

BUPRENORPHINE AND NALOXONE (Buprenorphine Hydrochloride And Naloxone Hydrochloride Dihydrate) Tablet [Actavis Pharma, Inc.]

February 14, 2015

Updated Date: Feb 11, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy

February 12, 2015

Conclusions There was no clinically meaningful impact of boceprevir on methadone or buprenorphine pharmacokinetics, suggesting that methadone/buprenorphine dose adjustments are not required upon coadministration with boceprevir. Individual patients may differ in their clinical experience and clinicians should maintain vigilance when coadministering these medications. (Source: European Journal of Clinical Pharmacology) MedWorm Sponsor Message: Directory of the […]

Read the full article →

Past-year gambling behaviour among patients receiving opioid substitution treatment

January 30, 2015

Conclusions: Gambling participation of the OST patients seemed to be somewhat similar compared with the Finnish general population, but gambling problems were more common among OST patients. Gender and age may not be very strong indicators of risk while screening problem gamblers among OST patients. Institution of a problem gambling screening program is recommended, and […]

Read the full article →

Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers

January 24, 2015

Conclusions Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in […]

Read the full article →

Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

January 10, 2015

CONCLUSIONS: Evaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00316277. PMID: 25562462 [PubMed – as supplied by publisher] (Source: Journal of Clinical Psychiatry) MedWorm Sponsor Message: Directory of the best January Sales in the […]

Read the full article →

Complete Care Medical Center Now Offering Same Week Appointments for…

December 30, 2014

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best […]

Read the full article →

ZUBSOLV (Buprenorphine Hydrochloride And Naloxone Hydrochloride) Tablet, Orally Disintegrating [Orexo US, Inc.]

December 26, 2014

Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Chronic pain volatility predicts outcomes of buprenorphine-naloxone for prescription opioid dependence

December 19, 2014

Aims: Prescription opioid (PO) dependence frequently co-occurs with chronic pain. Prior studies did not find poorer buprenorphine-naloxone (BUP-NLX) outcomes in chronic pain patients, but more dynamic indicators of chronic pain may impact treatment. We hypothesized that greater pain volatility would predict opioid use during BUP-NLX taper in adults with PO dependence and chronic pain. (Source: […]

Read the full article →

Does early response to buprenorphine-naloxone predict treatment outcome in prescription opioid dependence?

December 19, 2014

Aims: The 10-site Prescription Opioid Addiction Treatment Study, conducted in the NIDA Clinical Trials Network, examined different lengths of buprenorphine-naloxone (bup-nx) plus medical management, with or without additional counseling, for patients dependent upon prescription opioids. Among patients (N=360) receiving 12 weeks of bup-nx stabilization, 49% achieved successful opioid use outcomes at week 12. The aim […]

Read the full article →

← Previous Entries

Next Entries →